GenSpera, Inc. (OTCQB:GNSZ) reported the enrolment of the first patient in the Phase II clinical trial of its lead compound, G-202, in patients who have glioblastoma multiforme (GBM), the most prevalent type of primary brain cancer.

GenSpera, Inc. (OTCMKTS:GNSZ) reported the enrolment of the first patient in the Phase II clinical trial of its lead compound, G-202, in patients who have glioblastoma multiforme (GBM), the most prevalent type of primary brain cancer.

As quoted in the press release:

The trial is being conducted at UC San Diego Moores Cancer Center. This Phase II G-202 trial will treat up to 34 patients with GBM that has progressed or recurred after at least one other treatment.

Click here to read the GenSpera Inc. (OTCQB:GNSZ) press release

cancer Company News